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September 2018 thrombolytic intervention per se imposes an impact on BBB integrity. Delayed tPA treatment exaggerates I/R injury and causes excessive degradation of the proteins of TJ, AJ, and basement membrane and bleeding because of thrombolytic activity, which amplifies BBB disruption. 4 Paradoxically, the thrombolytic activity is required for the clinic use of tPA. Thus, a promising strategy to attenuate HT after tPA treatment is to target I/R injury.
T541 is a Chinese compound medicine consisting of total Astragalus saponins (AS), total salvianolic acids (SAAs), and total Panax notoginseng saponins (PNS) in a ratio of AS:SAA:PNS=5:4:1. The potential to attenuate myocardial I/R injury through regulation of energy metabolism has been demonstrated by our laboratory for astragaloside IV 5 -the main component of AS-and ginsenoside Rb1, 6 ginsenoside Rg1, 7 and notoginsenoside R1 8 -the main components of PNS and SAA. 9 Buyang Huanwu Decoction-a compound Chinese medicine containing AS as an ingredient-has been reported to enhance energy metabolism and maintain BBB integrity in mouse I/R model. 10 In view of the available results, we speculated that T541 is potentially able to lessen BBB disruption and attenuate HT after tPA treatment by upregulating energy metabolism. This study was aimed to test this speculation.
Methods
Data that support the findings of this study are available from the corresponding author on reasonable request. the Committee on the Ethics of Animal Experiments of Peking University Health Science Center (LA2016308). Carotid artery thrombosis model was established as described. 11 In short, animal was anesthetized by intraperitoneal injection of sodium pentobarbital (2%; 45 mg/kg), and right common carotid artery was isolated and wrapped with 1-mm wide filter paper infiltrated with 10% FeCl 3 for 3 minutes to induce thrombus formation, which was replaced by saline in sham group. Carotid artery thrombosis was detected over time as described below, and only those animals whose maximum thrombus blocked >80% artery diameter at 4.5 hours after ischemia onset were used for further experiments. Animals were then randomly divided into different groups and treated with tPA (10 mg/kg; Boehringer Ingelheim, Inc, Germany) with/without T541 (5, 10, or 20 mg/kg; Tasly Pharmaceutical, Co, Ltd, Tianjin, China; see Figure I in the online-only Data Supplement for details).
To study the effect of different components of T541 on the cerebral injury, single component groups of AS, SAA, and PNS and 2-component groups of AS+SAA, AS+PNS, and SAA+PNS were included (Table I in the online-only Data Supplement). All the groups in vivo were generated by random number table.
Cell Culture and Hypoxia/Reoxygenation In Vitro
Human brain microvascular endothelial cells (CRL-3245; American Type Culture Collection, Manassas, VA) were cultured under 1% O 2 for 4.5 hours, followed by reoxygenation for 3 hours to establish hypoxia/reoxygenation model. tPA 20 μg/mL with/without T541 (400, 40, 4, 0.4, or 0.04 μg/mL) was added just before reoxygenation (see Table II in the online-only Data Supplement for details). No difference was observed in cell viability between control and control+T541 groups (40, 4, and 0.4 μg/ mL) except for control+T541 400 μg/mL (Figure II in the onlineonly Data Supplement).
Dynamic Assessment of Carotid Artery Thrombosis and Cerebral Blood Flow
Carotid artery thrombosis was showed by acridine red labeled platelets. Cerebral blood flow (CBF) was determined by a laser Doppler perfusion imager (PeriScan PIM 3-1143; Jarfalla, Sweden). Both variables were recorded at baseline, 10 minutes, 4.5 hours, 5.5 hours (1 hour after drug treatment), 6.5 hours (2 hours after drug treatment), and 28.5 hours (24 hours after drug treatment) after FeCl 3 challenge, respectively ( Figure I in the online-only Data Supplement). For evaluation of albumin leakage from cerebral venules, FITC-labeled albumin (50 mg/kg; Sigma-Aldrich, St. Louis) was infused via femoral vein after craniotomy at 24 hours after treatment. The albumin leakage from cerebral venules was observed using an upright intravital fluorescent microscopy (BX51WT; Olympus, Japan) and expressed as I/V (I, the fluorescent intensity in interstitial tissue; V, the fluorescent intensity in cerebral venule).
Neurological Deficit Evaluation
Twenty-four hours post-reperfusion, neurological scores were evaluated according to modified neurological severity scores 12 and 15-point 
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neurological evaluation scale 13 (see Tables III and IV in the onlineonly Data Supplement for detailed criteria).
Assessment of Cerebral Infarction and Hemorrhage
Mice under anesthesia underwent cardiac perfusion 24 hours after drug treatment with precooled PBS at 4°C. Brains were cut into 5 slices of 1 mm in thickness. Infarction size was assessed by 2% 2,3,5-triphenyltetrazolium chloride staining. Hemoglobin content was measured using a hemoglobin colorimetric assay kit (Cayman Chemical, MI).
Determination of Cerebral Microvascular Injury and Energy Metabolism
Assessment of Evans blue extravasation and water content, vascular morphology inspection by electron microscopy, and measurement of TJ and basement membrane proteins using Western blot and immunofluorescence microscopy were undertaken at 24 hours. Energy metabolism was evaluated by the content of AMP, ADP, and ATP and activity of respiratory chain complexes using ELISA kits (see the online-only Data Supplement).
Data Analysis
Data were showed as mean±SEM and statistically analyzed using 2-way ANOVA (thrombus area, CBF, neurological deficit score, cell viability) or 1-way ANOVA (the others) with Bonferroni post hoc correction. P<0.05 was considered statistically significant.
Results
T541 Accelerates the Decrease in Carotid Artery Thrombi and Recovers CBF After tPA Treatment
Dynamic images of carotid artery thrombosis in different groups and related quantification are displayed in Figure 1A and 1B. As noticed, thrombus occurred obviously at 10 minutes after FeCl 3 stimulation. As a result, carotid distal blood flow fell to <20% of baseline at 15 minutes after ischemia onset ( Figure  III in the online-only Data Supplement). The thrombi persisted until 4.5 hours without significant changes in size if not intervened. Treatment with tPA reduced the thrombus size in a timedependent manner with significant reduction being found at 24 hours after treatment. The FeCl 3 -induced thrombosis is a complex process involving multiple factors. Collagen-dependent aggregation of platelets is generally accepted as a major contributor. In addition, fibrin network is also reported to participate in platelet recruitment, and the composition of the thrombus may change over time. 14 We have stained the thrombus by Martius scarlet blue fibrin staining, showing that the thrombi consisted of fibrin fibers (blue) 3 hours after FeCl 3 stimulation, which further increased in amount 4.5 hours after No effect on the thrombus size was observed when treated with T541 alone over time. However, there is significantly difference in thrombus area between thrombus+tPA and thrombus+tPA+T541 groups in all dosage from 1 hour after treatment to 24 hours, indicating that T541 strengthened the thrombolytic effect of tPA significantly in a dose-dependent manner.
CBF in ischemic hemisphere was recorded continuously ( Figure 1C and 1D) , which showed that CBF decreased significantly at 10 minutes and maintained by 4.5 hours if not intervened. Neither T541 nor tPA alone had effect on the reduced CBF at any time point examined. Treatment with tPA+T541 restored CBF in a dose-and time-dependent manner, whereas at 24 hours, tPA+T541 5 mg/kg, tPA+T541 10 mg/kg, and tPA+T541 20 mg/kg increased carotid thrombolytic rates to 64.40±1.76%, 85.38±0.64%, and 98.76±0.41% of sham level, respectively, which were significantly higher than that in tPA alone (45.53±5.07%; Table V in the onlineonly Data Supplement).
We quantified the area of carotid thrombus and CBF at 4.5 and 24 hours after drug treatment, respectively, showing that carotid recanalization rate is correlated with CBF (R 2 =0.956; P=0.003; Table VI in the online-only Data Supplement; Figure  V in the online-only Data Supplement).
T541 Elevates Survival Rate and Improves Neurological Scores
The survival rate of animals was recorded over time, and neurological scores were assessed 24 hours after drug treatment (Figure 2A and 2B) . Interestingly, except for Sham and Sham+T541 groups, the animals in thrombus group had the highest survival rate but poorest neurological scores as compared with other groups. The survival rate of tPA treatment group at 4.5 hours was 50.0%, comparable with clinical data 15 -a phenomenon likely attributable to HT ( Figure  VI in the online-only Data Supplement), which was improved by adding T541 at 20 mg/kg (81.8%). Importantly, addition of T541 at 20 mg/kg to tPA treatment group significantly improved neurological scores. On the contrary, addition of T541 at 5 or 10 mg/kg to tPA treatment group did not reveal significant effect on survival rate at 24 hours, though it did improve neurological scores. This result suggests the dose of T541 as an important determinant in clinic outcome.
T541-20 Protects BBB From Breakdown After tPA Treatment
Noting that T541 at 20 mg/kg benefited both survival rate and neurological scores, we assessed the effect of it on BBB 
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September 2018 breakdown after tPA treatment by test of Evans blue extravasation, albumin leakage, cerebral microvascular ultrastructure, and cerebral water content ( Figure 2C and 2D) . Impressively, all the results pointed toward a conclusion that BBB was disrupted by tPA treatment, and this disruption was protected by addition of T541 at 20 mg/kg. Morphological examination by transmission electron microscope and scanning electron microscope further confirmed this result showing a less perivascular edema in the ischemic penumbra of tPA+T541-20 group compared with tPAalone group. Perivascular edema compressed capillaries, leading to lower cerebral perfusion, which has been reversed by T541.
T541 Maintains the Integrity of Endothelial Cell Junctions After tPA Treatment
Endothelial cell TJ is an essential contributor to BBB. We thus first explored the effect of T541 on endothelial cell TJ by immunofluorescence in vivo and in vitro. tPA treatment caused a discontinuity of occludin staining around the periphery of endothelial cells, implying an impaired TJ ( Figure 3A) . Western blot showed that the impaired TJ integrity including the decreased expression of zonula occludens-1 and junctional adhesion molecule-1 in addition to occludin ( Figure 3B ). The decrease in the expression of VE-cadherin found by Western blot implied involvement of AJ as well in BBB breakdown after tPA treatment, consistent with the recognition that both TJ and AJ participate in maintaining BBB integrity. In vitro study using hypoxia/reoxygenation model further consolidated this notion ( Figure 3D ). Moreover, in vitro study revealed a decreased expression and disarrangement of JAM-1 in the cells after tPA treatment ( Figure 3C ). Dramatically, all aforementioned alterations caused by tPA were protected by addition of T541, highlighting the beneficial role of T541 in maintaining BBB integrity.
T541 Attenuates HT and Infarction After tPA Treatment
tPA treatment elicited an obvious HT and infarction in the mice with thrombi, which were attenuated significantly by addition of T541 (Figure 4A and 4C; Figures VII through XII in the online-only Data Supplement). tPA treatment-caused cerebral infarction was likely attributable to cell apoptosis via increasing the ratio of Bcl-2 (B-cell lymphoma 2)/Bax (Bcl-2-associated X protein). which was protected by addition of T541 both in vivo and in vitro ( Figure  XIII in the online-only Data Supplement). Hemorrhage after tPA treatment implied disruption of endothelium barrier, to which basement membrane acted as a major contributor. As expected, basement membrane of microvasculature was found disrupted in thrombus+tPA group, concurrent with a reduction of collagen IV and laminin-the 2 major constituents of basement membrane (Figure 4 ). Of note, the tPA-evoked change in basement membrane was prevented by addition of T541.
T541 Attenuates Energy Metabolism Disturbance and Oxidative Stress After tPA Treatment
We next assessed the energy metabolism and oxidative stress in different conditions, both of which are closely related to mitochondria function. TJs and AJs maintained BBB structure by combining with ATP-affinity cytoskeleton F-actin. 16 F-actin was depolymerized in endothelial cells after hypoxia/reoxygenation tPA and reassembled when adding T541 ( Figure 5A ). It may be the consequence of ATP5D (ATP synthase subunit) low expression and ATP deficiency. It was corroborated by Western blot and ELISA tests of cortex ( Figure 5B and 5C). Thrombolysis followed by tPA treatment resulted in a disturbed energy metabolism, which was improved by T541. Moreover, tPA combined with AS+PNS group inhibited ADP and AMP increase; and tPA combined with any group, including AS or PNS, inhibited AMP/ATP increase. The oxidative stress implicated high level of malondialdehyde and 8-Oxo-2′-deoxyguanosine; low activities of mitochondria complex I, II, and IV in tPA-treated ischemia cortex were recovered T541 at 20 mg/kg. Interestingly, addition of tPA with SAA or AS+SAA reduced the high content of 8-Oxo-2′-deoxyguanosine; and tPA with SAA+PNS recovered the activity of complex I.
Each ingredient of T541 contributed as separated role in mitochondria protection. AS and PNS were found beneficial in restoring energy metabolism and SAA efficient in oxidative stress. However, none of the ingredients alone or in combination of any 2 worked comparably with T541. This result further suggests the superiority of including multiple components in the medicine.
T541 Increases the Activity of Plasmin and Decreases the Activity of MMPs After tPA Treatment
We assessed the activity and content of plasmin and MMP (matrix metalloproteinase)-2/3/9 in plasma and cortex ( Figure 6 ). The results showed that tPA increased the activity of plasmin and MMPs in plasma in animals with thrombus. Administration of T541 together with tPA further increased the activity of plasmin, whereas AS, SAA, and PNS each alone or in combination had no effect. On the contrary, T541+tPA decreased the activity of MMPs compared with tPA alone. AS, SAA, and PNS each alone or in combination exhibited attenuating effect on activity of MMPs as well but to different degree depending on the MMP concerned. These results suggest that T541 may enhance the activity of plasmin to assist in thrombolysis and decreased the activity of MMPs to protect BBB. 
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Discussion
tPA is the sole management recommended for patients presenting with ischemic stroke. However, the risk of HT, particularly when applied later than 4.5 hours after onset of ischemia, limits the application of tPA in clinic. 17 In line with the clinic observation, the present study revealed that administration of tPA at 4.5 hours after onset of ischemia resulted in severe cerebral hemorrhage in mice, accompanied with cerebral infarction and a lower survival rate. Interestingly, tPA+T541 at 20 mg/kg significantly improved the thrombolysis efficiency and outcome of mice with thrombus, with reducing hemorrhage and infarction and elevating neurological scores. This result highlights T541 as a promising adjunctive therapy for tPA.
Hemorrhage after tPA treatment results from BBB disruption. Several structures, including endothelial cells TJ, AJ, and basement membrane, participate in formation of BBB.
18 BBB disruption initiates in ischemia, in which energy metabolism fails because of insufficient supply of oxygen and nutrition and impairment of mitochondria function. 19 Energy metabolism failure leads to a cascade of consequence, such as ATP depletion, a decrease in Na + -K + ATPase activity, 20 a rise in intracellular osmotic pressure, lactic acidosis, and disarrangement of F-actin, which together with induction of protease, that is, MMPs, contribute to BBB disruption. 21, 22 Delayed administration of tPA prolongs the ischemic impact on BBB and provokes reperfusion injury that further exaggerates the impairment of BBB by release of oxygen peroxide and apoptosis signaling from dysfunctional mitochondria. 23 Obviously, mitochondria play a key role in the initiation and progression of BBB breakdown in I/R injury, 24, 25 and strategy able to protect mitochondria is expected to attenuate BBB disruption and hemorrhage after tPA treatment. 26 The result of the present study shows that T541 may work as such strategy, as evidenced by its potential to restore mitochondria structure and function and maintain the expression of TJ and AJ proteins and collagen IV and laminin.
The finding of the present study is predicable considering our previously published results attenuating myocardial I/R injury. [6] [7] [8] [9] For example, 3,4-dihydroxyl-phenyl lactic acid, which was contained in SAA, significantly ameliorated the I/R-induced myocardial damage and apoptosis. 27 In this study, AS and PNS were found beneficial in inhibiting ADP/AMP energy metabolism disorders. SAAs were efficient in 8-Oxo-2′-deoxyguanosine content and complex I activity recovery. However, none of them worked as good as T541. This result likely suggests a necessity and superiority to include all the ingredients in T541, at least for the setting tested. The reason for this is at present unknown. Nonetheless, more study is required to elucidate the detailed mechanisms responsible for the effects of T541 observed, particularly the signaling pathway for each of the ingredients and any likely interaction between them.
There were only male mice used in this study because of the fear of estrogen interference and limited funding. Further study is needed to clarify whether sex difference exists in the effect of T541.
In conclusion, our study demonstrated that tPA administration at 4.5 hours after thrombosis exhibited a rising risk of angioedema and hemorrhage with undesirable outcomes, which was related to BBB disruption because of energy depletion and oxidative stress. All the insults after tPA treatment can be ameliorated by addition of T541, suggesting T541 as a new strategy that helps extend thrombolysis time window in clinic.
